# Study of IK-595 in RAS- or RAF-altered Advanced Tumors

> **NCT06270082** · PHASE1 · TERMINATED · sponsor: **Ikena Oncology** · enrollment: 75 (actual)

## Conditions studied

- Solid Tumor, Adult
- Colorectal Cancer
- Pancreatic Cancer
- Malignant Melanoma
- Ras (Kras or Nras) Gene Mutation
- BRAF Gene Mutation
- CRAF Gene Mutation
- Non-Small Cell Lung Carcinoma
- Thyroid Carcinoma
- Gliomas, Malignant

## Interventions

- **DRUG:** IK-595

## Key facts

- **NCT ID:** NCT06270082
- **Lead sponsor:** Ikena Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-18
- **Primary completion:** 2025-09-08
- **Final completion:** 2025-09-08
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Limited resources and strategic priorities
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270082, "Study of IK-595 in RAS- or RAF-altered Advanced Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06270082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*